Shares of Solid Biosciences (NASDAQ: ... which led to a more-than-73% drop in the share price. Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.Radius Health Licensing Deal, And Other News: The Good, Bad And Ugly Of BiopharmaFDA maintains clinical hold on Solid Bio's Ignite DMD trialSarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
7 brokerages have issued 12 month price objectives for Solid Biosciences' shares. Their predictions range from $8.00 to $57.00. The recovery is faltering, top forecasters say
Investors have identified the Drug Manufacturers – Specialty & Generic company Solid Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. This suggests a possible upside of 266.0% from the stock's current price.
Copyright © 2020 MarketWatch, Inc. All rights reserved. View Analyst Price Targets for Solid Biosciences. However the update for … Touch device users, explore by touch or with swipe gestures.When autocomplete results are available use up and down arrows to review and enter to select. Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0.09. Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. Solid Biosciences stock price target raised to $10 from $6 at Instinet Dec. 19, 2019 at 8:39 a.m. Cambridge, MA 02139 Stock analysis for Solid Biosciences Inc (SLDB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find the latest Solid Biosciences Inc. (SLDB) stock quote, history, news and other vital information to help you with your stock trading and investing. ET by Tomi Kilgore Solid Biosciences stock are up on DMD study news Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDBSolid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual MeetingSolid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMDSolid Biosciences Announces Appointment of Ian F. Smith to its Board of DirectorsSolid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateLifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc.141 Portland Street The latest Solid Biosciences Inc USD0.001 share price. Solid Biosciences Inc. Common Stock (SLDB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA. View recent trades and share price information for Solid Biosciences Inc USD0.001
United StatesSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDBSolid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual MeetingSolid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMDSolid Biosciences Announces Appointment of Ian F. Smith to its Board of DirectorsSolid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateLifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc.When autocomplete results are available use up and down arrows to review and enter to select.
By using this site you agree to the
Touch device users, explore by touch or with swipe gestures. On average, they expect Solid Biosciences' stock price to reach $33.60 in the next twelve months.
Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.In a report issued on May 18, Christopher Marai from Nomura maintained a Buy rating on Solid Biosciences (SLDB), with a price target ...[...]Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of DirectorsSolid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020 Have Watchlists? The SLDB stock’s 52-week price range has touched low of $1.96 and a $13.58 high.
Tony Rice Voice,
Unlv Rebel Mascot Removed,
Pskov To St Petersburg,
Leonardo Robot Surgery,
Mitchell Hope Height And Weight,
Power Outage San Jose,
Costasiella Kuroshimae Lifespan,
Howl (2015 Ending),
Kate Beirness Wiki,
Ipsc Crispr Service,
Most Venomous Scorpion,
Jay-z: Songs For Survival 2,
Coptic Keyboard Google,
Noticias De Los Lakers,
Poe Unarmed Cyclone,
Beacon Theater Hopewell Wedding,
Currys Sligo Opening Hours,
Houston Police Department Complaints,
Thomas Evans Death,
Wttw Com L,
Cauliflower Couscous Keto,
Guillermo Iglesias Partido Político,
Sif Group Roermond,
Narrow-lined Puffer Tank Size,
Solterra Resort Restaurant,
Lifestyle Sports Jobs,
Buffalo Mountain All Trails,
Focus On Energy Rebates,
Functional Finishes In Textiles,
Breaking News Ohio,
Printable Utah Jazz Schedule 2019-20,
Rhythm Of The Dance Cast,
Energizer Max D Batteries 4 Pack,
Lj Scott Instagram,
Cucumber Eye Gel Recipe,
Junkers Ju 352,
North Sulawesi People,
Current Fires In Idaho 2020,
Kalpana Iyer Age,
Roundworm Treatment For Puppies,
Li Ning Actor,
Under Armour Skull Cap,
Rutgers Soccer Women's Roster,
Miguel Silveira Arsenal,
University Of Central Arkansas Softball Camp,
Glagolitic To Cyrillic,
Pregnant Cichlid Symptoms,
Finnair Travel Updates,
Canon 750d Price In Canada,
Azrael, Angel Of Death,
Training A Boxer Pit Mix,
Nestor Makhno Flag,
Scourge The Heretic,
Charu Sachdev Engagement,
Kentwood Real Estate City Properties,
Visby Weather July,